Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 + Bevacizumab vs Sintilimab + Bevacizumab in First-Line Advanced Hepatocellular Carcinoma
NCT07813572Phase 3Not yet recruiting
- Sponsor
- Zelgen
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nilvanstomig in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zelgen. Primary endpoints: Progression-free survival up to 3 years and Overall survival up to 5 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nilvanstomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07813572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07813572.